Tgf-β-activated kinase-1: A potential prognostic marker for clear cell renal cell carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 1, 2013, Pages 315-320

  Wei, Can ^a,b,c   Lai, Yong Qing ^a   Li, Xian Xin ^a,b   Ye, Jiong Xian ^a,b,c  

^a PEKING UNIVERSITY SHENZHEN HOSPITAL   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL   (China)

Author keywords

Clear cell renal cell carcinoma; Prognosis; TAK1; Tumorigenesis

Indexed keywords

EID: 84877156267     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.1.315     Document Type: Article

References (43)

1. Bergers G, Brekken R, McMahon G, et al (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol, 2, 737-44.
2. Chantrain CF, Shimada H, Jodele S, et al (2004). Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res, 64, 1675-86.
3. Cui ZW, Xia Y, Ye YW, et al (2012). RALY RNA binding proteinlike reduced expression is associated with poor prognosis in clear cell renal cell carcinoma. Asian Pac J Cancer Prev, 13, 3403-8.
4. Delaney JR, Mlodzik M (2006). TGF-beta activated kinase-1: new insights into the diverse roles of TAK1 in development and immunity. Cell Cycle, 5, 2852-5.
5. Edlund S, Bu S, Schuster N, et al (2003). Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGFbeta- activated kinase 1 and mitogen-activated protein kinase kinase 3. Mol Biol Cell, 14, 529-44.
6. Farina AR, Coppa A, Tiberio A, et al (1998). Transforming growth factor-beta1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer, 75, 21-30.
7. Fuhrman SA, Lasky LC, Limas C (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol, 6, 655.
8. Janzen NK, Kim HL, Figlin RA, et al (2003). Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin N Am, 30, 843-52.
9. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D(2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
10. Jiang Z, Chu PG, Woda BA, et al (2006). Analysis of RNAbinding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol, 7, 556-64.
11. Kajino-Sakamoto R, Inagaki M, Lippert E, et al (2008). Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol, 181, 1143-52.
12. Karin M, Greten FR (2005). NF-[kappa]B: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5, 749-59.
13. Kaur S, Wang F, Venkatraman M, Arsura M (2005). X-linked inhibitor of apoptosis (XIAP) inhibits c-Jun N-terminal kinase 1 (JNK1) activation by transforming growth factor beta1 (TGF-beta1) through ubiquitin-mediated proteosomal degradation of the TGF-beta1-activated kinase 1 (TAK1). J Biol Chem, 280, 38599-608.
14. Kondo M, Osada H, Uchida K, et al (1998). Molecular cloning of human TAK1 and its mutational analysis in human lung cancer. Int J Cancer, 75, 559-63.
15. Lam JS, Shvarts O, Leppert JT, et al (2005). Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol, 173, 1853-62.
16. Lane BR, Babineau D, Kattan MW, et al (2007). A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urology, 178, 429-34.
17. Levi F, Ferlay J, Galeone C, et al (2008). The changing pattern of kidney cancer incidence and mortality in Europe. BJU Int, 101, 949-58.
18. Liu HH, Xie M, Schneider MD, Chen ZJ (2006). Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci USA, 103, 11677-82.
19. Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta] CT method. Methods, 25, 402-8.
20. Li X, Huang Y, Xia J, et al (2011). CXCR4 expression in patients with high-risk locally advanced renal cell carcinoma can independently predict increased risk of disease progression and poor overall survival. Asian Pac J Cancer Prev, 12, 3313-8.
21. Melisi D, Xia Q, Paradiso G, et al (2011). Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst, 103, 1190-204.
22. Ninomiya-Tsuji J, Kishimoto K, Hiyama A, Inoue J, Cao Z, Matsumoto K (1999). The kinase TAK1 can activate the NIK-I?B as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature, 398, 252-6.
23. Nogueira M, Kim HL (2008). Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol, 26, 113-24.
24. Omori E, Morioka S, Matsumoto K, et al (2008). TAK1 regulates reactive oxygen species and cell death in keratinocytes, which is essential for skin integrity. J Biol Chem, 283, 26161-8.
25. Pasparakis M (2009). Regulation of tissue homeostasis by NF- ?B signalling: implications for inflammatory diseases. Nat Rev Immunol, 9, 778-88.
26. Safina A, Ren M-Q, Vandette E, Bakin AV, et al (2008). TAK1 is required for TGF-[beta]1-mediated regulation of matrix metalloproteinase-9 and metastasis. Oncogene, 27, 1198-207.
27. Safina A, Sotomayor P, Limoge M, et al (2011). TAK1-TAB2 signaling contributes to bone destruction by breast carcinoma cells. Mol Cancer Res, 9, 1042-53.
28. Safina A, Vandette E, Bakin AV, et al (2007). ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells. Oncogene, 26, 2407-22.
29. Sato S, Sanjo H, Takeda K, et al (2005). Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol, 6, 1087-95.
30. Schrader A, Sevinc S, Olbert P, et al (2008). Gender-specific characteristics and survival of renal cell carcinoma. Urologe A, 47, 1182, 4-6.
31. Shibuya H, Iwata H, Masuyama N, et al (1998). Role of TAK1 and TAB1 in BMP signaling in early Xenopus development. Embo J, 17, 1019-28.
32. Shim JH, Xiao C, Paschal AE, et al (2005). TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev, 19, 2668-81.
33. Shvarts O, Seligson D, Lam J, et al (2005). p53 is an independent predictor of tumor recurrence and progression after nephrectomy in patients with localized renal cell carcinoma. J Urol, 725-8.
34. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H (2005). Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem, 280, 7359-68.
35. Suarez-Cuervo C, Merrell MA, Watson L, et al (2004). Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis, 21, 525-33.
36. Takaesu G, Ninomiya-Tsuji J, Kishida S, et al (2001). Interleukin-1 (IL-1) receptor-associated kinase leads to activation of TAK1 by inducing TAB2 translocation in the IL-1 signaling pathway. Mol Cell Biol, 21, 2475-84.
37. Tamaskar I, Choueiri TK, Sercia L, et al (2007). Differential expression of caveolin 1 in renal neoplasms. Cancer, 110, 776-82.
38. Tostain J, Li G, Gentil-Perret A, Gigante M (2010). Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer, 46, 3141-8.
39. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA (2006). The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol, 7, 851-8.
40. Wei X, Zhou L, Hu L, Huang Y (2012). Tanshinone IIA arrests cell cycle and induces apoptosis in 786-O human renal cell carcinoma cells. Oncol Lett, 3, 1144-8.
41. Wood CG (2006). Molecular markers of prognosis in renal cell carcinoma: Insight into tumor biology helps define risk and provides targets for therapy. J Surg Oncol, 94, 264-5.
42. Yamaguchi K, Shirakabe K, Shibuya H, et al (1995). Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science, 270, 2008-11.
43. Yu XY, Zhang Z, Zhang GJ, Guo KF, Kong CZ (2012). Knockdown of Cdc25B in renal cell carcinoma is associated with decreased malignant features. Asian Pac J Cancer Prev, 13, 931-5.